Advertisement

Cholesterol is the Cause of Atherosclerosis

      Although some investigators have considered cholesterol the cause of atherosclerosis for several decades,
      • Roberts W.C.
      Extreme hypercholesterolemia = malignant atherosclerosis.
      • Roberts W.C.
      The role of cholesterol in atherosclerosis.
      • Roberts W.C.
      Atherosclerotic risk factors: are there ten or is there only one?.
      • Roberts W.C.
      Lipid-lowering therapy after an atherosclerotic event.
      • Roberts W.C.
      Getting cardiologists interested in lipids.
      • Roberts W.C.
      Preventing and arresting coronary atherosclerosis.
      • Roberts W.C.
      The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease.
      • Roberts W.C.
      The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
      • Roberts W.C.
      Shifting from decreasing risk to actually preventing and arresting atherosclerosis.
      • Roberts W.C.
      Twenty questions on atherosclerosis.
      • Roberts W.C.
      Getting more people on statins.
      • Roberts W.C.
      Atherosclerosis: its cause and its prevention.
      • Roberts W.C.
      The cause of atherosclerosis.
      • Roberts W.C.
      Evaluating lipid-lowering trials in the twenty-first century.
      • Roberts W.C.
      It's the cholesterol, stupid!.
      26 authors, mainly from Europe, in April 2017, published an article titled “Low-density lipoproteins cause atherosclerotic cardiovascular disease…,” a consensus statement from the European Atherosclerosis Society Consensus Panel.
      • Ference B.A.
      • Ginsberg H.N.
      • Graham I.
      • Ray K.K.
      • Packard C.J.
      • Bruckert E.
      • Hegele R.A.
      • Krauss R.M.
      • Raal F.J.
      • Schunkert H.
      • Watts G.F.
      • Borén J.
      • Fazio S.
      • Horton J.D.
      • Masana L.
      • Nicholls S.J.
      • Nordestgaard B.J.
      • van de Sluis B.
      • Taskinen M.J.
      • Tokgözoğlu L.
      • Landmesser U.
      • Laufs U.
      • Wiklund O.
      • Stock J.K.
      • Chapman M.J.
      • Catapano A.L.
      Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
      I was glad to see the article that soundly supports the view that cholesterol is the cause of atherosclerosis. Although I found the article unnecessarily difficult, the message is loud and clear. So when your physician recommends a statin drug or ezetimibe or one of the PCSK-9 inhibitors, take it. These drugs are safer than almost any drug one can put in his/her mouth.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roberts W.C.
        Extreme hypercholesterolemia = malignant atherosclerosis.
        Am J Cardiol. 1984; 54: 242-243
        • Roberts W.C.
        The role of cholesterol in atherosclerosis.
        Cardiovasc Risk Factors. 1988; 1: 2-5
        • Roberts W.C.
        Atherosclerotic risk factors: are there ten or is there only one?.
        Am J Cardiol. 1989; 64: 552-554
        • Roberts W.C.
        Lipid-lowering therapy after an atherosclerotic event.
        Am J Cardiol. 1989; 64: 693-695
        • Roberts W.C.
        Getting cardiologists interested in lipids.
        Am J Cardiol. 1993; 72: 744-745
        • Roberts W.C.
        Preventing and arresting coronary atherosclerosis.
        Am Heart J. 1995; 130: 580-600
        • Roberts W.C.
        The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease.
        Am J Cardiol. 1996; 78: 377-378
        • Roberts W.C.
        The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
        Am J Cardiol. 1997; 80: 106-107
        • Roberts W.C.
        Shifting from decreasing risk to actually preventing and arresting atherosclerosis.
        Am J Cardiol. 1999; 83: 816-817
        • Roberts W.C.
        Twenty questions on atherosclerosis.
        Proc (Bayl Univ Med Cent). 2000; 13: 139-143
        • Roberts W.C.
        Getting more people on statins.
        Am J Cardiol. 2002; 90: 683-685
        • Roberts W.C.
        Atherosclerosis: its cause and its prevention.
        Am J Cardiol. 2006; 98: 1550-1555
        • Roberts W.C.
        The cause of atherosclerosis.
        Nutr Clin Pract. 2008; 23: 464-467
        • Roberts W.C.
        Evaluating lipid-lowering trials in the twenty-first century.
        Am J Cardiol. 2009; 103: 1325-1328
        • Roberts W.C.
        It's the cholesterol, stupid!.
        Am J Cardiol. 2010; 106: 1364-1366
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • Ray K.K.
        • Packard C.J.
        • Bruckert E.
        • Hegele R.A.
        • Krauss R.M.
        • Raal F.J.
        • Schunkert H.
        • Watts G.F.
        • Borén J.
        • Fazio S.
        • Horton J.D.
        • Masana L.
        • Nicholls S.J.
        • Nordestgaard B.J.
        • van de Sluis B.
        • Taskinen M.J.
        • Tokgözoğlu L.
        • Landmesser U.
        • Laufs U.
        • Wiklund O.
        • Stock J.K.
        • Chapman M.J.
        • Catapano A.L.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur Heart J. 2017; 38: 2459-2472
        • Giugliano R.P.
        • Wiviott S.D.
        • Blazing M.A.
        • De Ferrari G.M.
        • Park J.
        • Murphy S.A.
        • White J.A.
        • Tershakovec A.M.
        • Cannon C.P.
        • Braunwald E.
        Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a pre-specified analysis of the IMPROVE-IT Trial.
        JAMA Cardiol. 2017; 2: 598-607